FDA U-Turns on Rare Disease Treatment: What it Means for Patients
Summary
The U.S. Food and Drug Administration (FDA) has reversed its earlier decision and will now allow the biotech company uniQure to seek accelerated approval for its drug AMT-130, which aims to treat Huntington’s disease. This drug could be the first treatment to slow the progression of this rare, fatal brain disease.Key Facts
- The FDA previously called uniQure’s drug a "failed product" in March but now supports accelerated approval efforts.
- AMT-130 is a gene therapy intended to reduce a harmful protein in the brain that causes Huntington’s disease.
- Huntington’s disease is a rare inherited condition that gradually damages brain cells and has no current cure.
- The treatment is given once through surgery directly into the brain.
- Early results suggest patients with higher doses of AMT-130 show slower disease progression.
- UniQure plans to submit a Biologics License Application in the third quarter of 2026 using data from a three-year trial.
- The FDA has given AMT-130 special designations to speed its development, including Regenerative Medicine Advanced Therapy and Breakthrough Therapy designations.
- The FDA’s decision has been welcomed by patient advocacy groups who see it as renewed hope for families affected by Huntington’s disease.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.